Skip to content
About Us
Company Profile
History
Management
Investors
Research & Development
Mode of Action
Clinical Development
Publications
Vascular Integrity
Adrenomedullin
Sepsis & Septic Shock
News & Events
Contact
About Us
Company Profile
History
Management
Investors
Research & Development
Mode of Action
Clinical Development
Publications
Vascular Integrity
Adrenomedullin
Sepsis & Septic Shock
News & Events
Contact
Article in ENDPOINTS: Wellington, HBM lead €24M round as Adrenomed preps septic shock treatment for human testing
27. November 2018
by Amber Tong.
Go to the article